DUBLIN, April 18, 2018 /PRNewswire/ --
The "Integrated Devices for Reconstituting Injectables" report has been added to ResearchAndMarkets.com's offering.
The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed.
Alternatively, proteins can be formulated as powders (lyophilization) and must be reconstituted prior to injection. Historically, this was accomplished by including a disposable syringe and diluent vial for manual reconstitution. As the number of drugs developed for self-administration has grown, devices that integrate a reconstitution step with the injection step have gained traction.
As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.
What You Will Learn
- What is the impact of lyophilized injectable drugs on today's therapeutic market, how are they packaged, and who markets them?
- Who are the suppliers of integrated reconstitution devices, and what is their market impact?
- What are the major factors driving the demand for integrated devices for injectable drug reconstitution?
- What is the relative impact of integrated reconstitution systems to OEM or standalone reconstitution devices and how will this change by the end of the decade?
- What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?
- What is the role of integrated drug reconstitution systems on drug life cycle management?
- What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?
Who Should Read this Report
- Drug Developers
- Device Suppliers
- Clinical Trial Mgmt
- Pharma Managers
- Biotech Managers
- Drug Marketers
- Industry Strategists
- Financial Analysts
- Management Consultants
- Clinical Managers
- Drug Distributors
- Pharma Regulators
- FDA Consultants
- Managed Care Managers
Key Topics Covered:
1. Executive Summary
2. Drug Reconstitution Market Dynamics
- Evolution in Device Design
- Formulation Factors
- Product Specific Device Development
- Specialty Injection Device Demand Drivers
- Chronic Conditions and Self-Administration
- The Growth of Biologicals
- Formulation and Dosing
- Shifting Patient Demographics
- Drug Economics, Safety and Compliance
- Device Design and Innovation
- Competitive Landscape
- Technology Market Drivers
3. Integrated Devices for Reconstituting Injectables
- Dual Chamber Cartridges
- Dual Chamber Injectors
- Dual Chamber Syringes
- Wearable Device Automated Reconstitution System
4. Dual Chamber Syringe & Injector Device Assessments
- Product-Specific Devices
- Specialty Devices
- OEM Devices
5. Therapeutic Segments - Market Data & Forecasts
- Glycemic Control
- Hereditary Conditions
- Hormone Replacement
- Infectious Disease
- Metabolic Conditions
- Reproductive Health
- Other Therapeutic Segments
6. Market Factors
- Device Product Strategies
- Device Economics
- Product Branding
- Direct-to-Consumer Marketing
- Managed Care Trends
7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/b79227/global_integrated?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets